Bleb-related endophthalmitis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{SI}} | {{SI}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{SaraM}} | ||
==Overview== | ==Overview== | ||
Bleb-related endophthalmitis (BRE) is the second most frequent cause of postoperative endophthalmitis after acute and chronic post-cataract surgery endophthalmitis. | |||
==Historical Perspective== | ==Historical Perspective== | ||
| Line 16: | Line 17: | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
The incidence of bleb-related endophthalmitis is approximately range from 200 to 1300 per 100,000 individuals with . | |||
It's incidence is reported to be between 0.2% to 1.3%,2,3 and is more common with the use of antiproliferative agent (up to 3%) and even higher when the bleb is placed inferiorly (up to 9.4%). | |||
==Risk Factors== | ==Risk Factors== | ||
*Bleb leakage (increase the risk of bleb infection 26 fold) | |||
**General conjunctival thinning | |||
**Reduced cellularity | |||
** Avascular bleb | |||
**Use of anti-metabolites (such as [[5-fluorouracil|5-fluorouracil (5-FU)) | |||
**Use of Mitomycn-C (MMC) | |||
==Screening== | ==Screening== | ||
| Line 27: | Line 36: | ||
===Prognosis=== | ===Prognosis=== | ||
A single-center retrospective review from the 1990s showed that the 5 year risk of blebitis and that of BAE is 6.3% and 7.5%, respectively. | |||
==Diagnosis== | ==Diagnosis== | ||
Revision as of 17:32, 25 July 2016
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mehrsefat, M.D. [2]
Overview
Bleb-related endophthalmitis (BRE) is the second most frequent cause of postoperative endophthalmitis after acute and chronic post-cataract surgery endophthalmitis.
Historical Perspective
Classification
Pathophysiology
Causes
Epidemiology and Demographics
The incidence of bleb-related endophthalmitis is approximately range from 200 to 1300 per 100,000 individuals with . It's incidence is reported to be between 0.2% to 1.3%,2,3 and is more common with the use of antiproliferative agent (up to 3%) and even higher when the bleb is placed inferiorly (up to 9.4%).
Risk Factors
- Bleb leakage (increase the risk of bleb infection 26 fold)
- General conjunctival thinning
- Reduced cellularity
- Avascular bleb
- Use of anti-metabolites (such as [[5-fluorouracil|5-fluorouracil (5-FU))
- Use of Mitomycn-C (MMC)
Screening
Natural History, Complications, and Prognosis
Natural History
Complications
Prognosis
A single-center retrospective review from the 1990s showed that the 5 year risk of blebitis and that of BAE is 6.3% and 7.5%, respectively.